Abstract
Background and Aim: Minocycline therapy for acne vulgaris is associated with the occasional induction of various types of unsightly and often persistent hyperpigmentation, which is frequently resistant to hydroquinone treatment. Pigment-specific lasers have achieved some success with multiple treatment sessions. Recently, the picosecond domain 755 nm alexandrite laser (ps-Alex) has attracted attention in tattoo removal. The present study reports on the successful treatment, in a single ps-Alex session, of minocycline-associated pigmentation. Subject and method: Subsequent to a course of minocycline, a 28-year-old Asian female developed persistent type 2 minocycline-related pigmentation on the bilateral lower extremities which was recalcitrant to hydroquinone treatment. The patient had a test treatment on a small area with a Q-switched ruby laser and the ps-Alex, following which the ps-Alex was selected for the actual treatment (spot size, 2 mm; fluence, 6.37 J/cm²; pulsewidth, 750 ps) on one leg first, followed later by the contralateral leg. Results: Rapid clearance of the pigmentation was noted after a single ps-Alex session on both limbs without prolonged post-inflammatory hyperpigmentation (PIH). At one year post-treatment, clearance had been maintained. Conclusions: Our results in this single case strongly suggest that the novel 755-nm ps-Alex laser is both safe and very effective for the treatment of type 2 minocycline-induced hyperpigmentation even in PIH-prone type IV Asian skin. Further trials with larger patient populations are warranted to confirm this optimistic result.
Author supplied keywords
Cite
CITATION STYLE
Sasaki, K., Ohshiro, T., Ohshiro, T., Sakio, R., Fukazawa, E., Toriumi, M., & Ebihara, T. (2017). Type 2 minocycline-induced hyperpigmentation successfully treated with the novel 755 nm picosecond alexandrite laser–a case report. Laser Therapy, 26(2), 137–144. https://doi.org/10.5978/islsm.17-CR-03
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.